Korea BNC Acquires 44,210 Shares of Dongin Biotech for Business Diversification and Management Participation

[Asia Economy Reporter Lee Jung-yoon] Korea BNC announced on the 13th that it will acquire 44,210 shares of Dongin Biotech, a reagent and testing equipment wholesale and retail company, for 12 billion KRW.

After acquiring the shares, Korea BNC's stake in Dongin Biotech will be 63.2%. The purpose of the acquisition is to strengthen existing business capabilities, diversify business, and participate in management through securing management rights. The scheduled date of share acquisition is July 18 of this year.